PMN · ProMIS Neurosciences Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Nov 28, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Nov 28, 2025.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. ProMIS reported blinded six-month interim data from the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer's patients showing zero ARIA-E cases and directionally favorable biomarker movements (plasma pTau217 down ~15%, CSF MTBR-tau243 down ~13.3%), with unblinded 12-month topline results including cognitive outcomes expected in Q1 2027; the company ended Q2 with $53.4 million in cash, expected to fund operations through 2027.
- + Blinded interim PRECISE-AD analysis showed zero ARIA-E cases across all 136 safety-evaluable participants, including APOE4 homozygotes.
- + Blinded pooled biomarker data showed directionally favorable declines in plasma pTau217 (~15%) and CSF MTBR-tau243 (~13.3%), consistent with the trial's 75% active-drug allocation.
- + Cash position strengthened to $53.4 million with runway through 2027, beyond the anticipated Q1 2027 PRECISE-AD topline readout.
- + Pipeline advancing with PMN267 (TDP-43/ALS) progressing through IND-enabling studies and PMN442 (alpha-synuclein) advancing toward IND-enabling studies.
- + Company presented first human evidence of Aβ oligomer target engagement and removal by PMN310 at AAIC 2026.
- − Net loss widened to $11.7 million in Q2 2026 from $10.1 million in Q2 2025, with R&D expense rising to $9.5 million.
- − Accumulated deficit grew to $150.4 million as of June 30, 2026, reflecting continued operating losses.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMN
this stock
ProMIS Neurosciences Inc.
|
$121.60M | +98.5% | — | — | 2.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Nov 28, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMN | +5.1% | -8.3% | -23.0% | +3.8% | +98.5% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +6.3% | -6.6% | -40.8% | +4.1% | +86.5% |